What is the clinical evidence from this study?

Study design: Review. Population: Hypertension. Intervention: Non-peptidic direct renin inhibitors.

May 26, 2008Expert Opinion on Therapeutic Patents

Recent advances in the discovery of non-peptidic direct renin inhibitors as antihypertensives: new patent applications in years 2000 – 2008

View Full Paper

Ask AI

Bookmark

Key result

Non-peptidic direct renin inhibitors have shown increasing structural diversity in patents from 2000-2008, with several novel small-molecule candidates advancing to Phase II clinical trials.

Design

Review

Authors

FYFumiaki YokokawaNovartis (United States)JMJürgen MaibaumNovartis (China)

Discussion

Member takes

Implication

Patent trends may guide renin inhibitor design; leaves open clinical success beyond Phase II.

Structured PICO

Intervention

Non-peptidic direct renin inhibitors

This review highlights the structural diversity and development of novel non-peptidic direct renin inhibitors for hypertension based on patents from 2000-2008.

Cite This Study

Yokokawa et al. (2008) conducted a review in Hypertension. Non-peptidic direct renin inhibitors was evaluated. Non-peptidic direct renin inhibitors have shown increasing structural diversity in patents from 2000-2008, with several novel small-molecule candidates advancing to Phase II clinical trials.

synapsesocial.com/papers/6a130f03c031bb6829a7cb0a https://doi.org/10.1517/13543776.18.6.581

Topics

Hypertension management

View Full Paper

Ask AI

Bookmark

Recent advances in the discovery of non-peptidic direct renin inhibitors as antihypertensives: new patent applications in years 2000 – 2008

Discussion

Member takes

Implication

Structured PICO

Cite This Study

Topics

Recent advances in the discovery of non-peptidic direct renin inhibitors as antihypertensives: new patent applications in years 2000 – 2008

Discussion

Member takes

Implication

Structured PICO

Cite This Study

Also Consider

Topics

Also Consider